Sareum Holdings (SAR) Price & Analysis

Compare

26 Followers

SAR Stock Chart & Stats

15.00 p

0.10 p(0.44%)

At close: Jan 09 4:00 PM EST

15.00 p

0.10 p(0.44%)

Day’s Range― - ―

52-Week Range9.50 p - 29.00 p

Previous CloseN/A

Volume41.80K

Average Volume (3M)619.72K

Market Cap

£20.71M

Enterprise Value17.16M

Total Cash (Recent Filing)£3.55M

Total Debt (Recent Filing)£0.00

Price to Earnings (P/E)―

Beta-0.64

Next Earnings

Oct 26, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding138,065,170

10 Day Avg. Volume1,134,615

30 Day Avg. Volume619,716

Financial Highlights & Ratios

PEG Ratio0.31

Price to Book (P/B)8.68

Price to Sales (P/S)0.00

P/FCF Ratio-7.75

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.02

Revenue Forecast (FY)£43.15M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA lack of reported debt materially reduces fixed obligations and financing risk, giving management flexibility to time partnerships, R&D spend, or equity raises. Over 2–6 months this structural strength improves solvency resilience versus leveraged peers in biotech development cycles.

Narrowing Cash Outflow TrendA reduction in cash outflow signals better cost control or project prioritisation, which can extend runway and reduce immediate financing needs. If sustained, this trend supports continuation of discovery programs and strengthens negotiating position in partnership talks over months.

Licensing/partnership Revenue ModelA business model focused on licensing, milestones and collaboration fees decouples value creation from large commercial infrastructure and can produce non-dilutive milestone cash. Structurally this allows value realisation through partnerships even without internal commercialization capacity.

Bears Say

Pre-revenue With Persistent LossesBeing pre-revenue with recurring operating losses means the company cannot self-fund R&D or operations; it must rely on external financing or partner milestones. Over months this constrains strategic optionality and raises execution risk if funding or deals are delayed.

Sustained Negative Cash FlowNegative operating and free cash flow across reporting periods indicate the business consumes capital faster than it generates it. Even with recent narrowing, sustained negative cash flow pressures liquidity and increases the probability of dilutive financing or partnership-driven conditional funding.

Dependence On External Funding And Volatile EquitySmall, volatile equity and asset fluctuations show the balance sheet is shaped by fundraising/events rather than consistent internal cash generation. This structural reliance on external capital raises execution and dilution risk and can lengthen timelines if capital markets or partners retreat.

Sareum Holdings News

Sareum Restarts Key Toxicology Study as TYK2 Pipeline and Partnering Drive Half-Year Progress

The latest announcement is out from Sareum Holdings ( ($GB:SAR) ). Sareum Holdings reported half-year results to 31...

4d ago

Sareum to Release Interim Results and Host Live Investor Presentation

Sareum Holdings ( ($GB:SAR) ) has issued an update. Sareum Holdings said it will publish its unaudited interim...

13d ago

Sareum Restarts Phase 2-Enabling Toxicology Programme for Lead Autoimmune Drug SDC-1801

Sareum Holdings ( ($GB:SAR) ) has shared an announcement. Sareum Holdings has restarted its Phase 2-enabling toxicology programme...

27d ago

Sareum Holdings Passes All Resolutions at AGM, Strengthening Governance

Sareum Holdings ( ($GB:SAR) ) has shared an announcement. Sareum Holdings plc announced that all resolutions at its...

3M ago

Sareum Holdings Advances Pipeline and Strengthens Portfolio

Sareum Holdings ( ($GB:SAR) ) has shared an update. Sareum Holdings has made significant progress in its pipeline,...

3M ago

Sareum Holdings Announces AGM and Releases Annual Report

Sareum Holdings ( ($GB:SAR) ) has provided an update. Sareum Holdings PLC has announced its Annual General Meeting...

4M ago

Sareum Holdings Enhances Financial Advisory Team with New Joint Broker Appointment

The latest announcement is out from Sareum Holdings ( ($GB:SAR) ). Sareum Holdings PLC has appointed Singer Capital...

5M ago

Sareum Holdings Reports Progress in Drug Development and Strategic Collaborations

Sareum Holdings ( ($GB:SAR) ) has issued an announcement. Sareum Holdings PLC announced its unaudited financial results for...

5M ago

Sareum Holdings Discontinues Toxicology Study for SDC-1801 Amid Safety Concerns

Sareum Holdings ( ($GB:SAR) ) has issued an announcement. Sareum Holdings has discontinued its 16-week GLP preclinical toxicology...

5M ago

Sareum Holdings to Announce Financial Results and Host Investor Presentation

Sareum Holdings ( ($GB:SAR) ) has issued an announcement. Sareum Holdings PLC announced it will release its financial...

5M ago

SAR FAQ

What was Sareum Holdings PLC’s price range in the past 12 months?

Sareum Holdings PLC lowest share price was 9.50 p and its highest was 29.00 p in the past 12 months.

What is Sareum Holdings PLC’s market cap?

Sareum Holdings PLC’s market cap is £20.71M.

When is Sareum Holdings PLC’s upcoming earnings report date?

Sareum Holdings PLC’s upcoming earnings report date is Oct 26, 2026 which is in 225 days.

How were Sareum Holdings PLC’s earnings last quarter?

Sareum Holdings PLC released its earnings results on Mar 12, 2026. The company reported -0.012 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.012 p.

Is Sareum Holdings PLC overvalued?

According to Wall Street analysts Sareum Holdings PLC’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sareum Holdings PLC pay dividends?

Sareum Holdings PLC does not currently pay dividends.

What is Sareum Holdings PLC’s EPS estimate?

Sareum Holdings PLC’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sareum Holdings PLC have?

Sareum Holdings PLC has 138,065,170 shares outstanding.

What happened to Sareum Holdings PLC’s price movement after its last earnings report?

Sareum Holdings PLC reported an EPS of -0.012 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.143%.

Which hedge fund is a major shareholder of Sareum Holdings PLC?

Currently, no hedge funds are holding shares in GB:SAR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sareum Holdings PLC

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.